{
 "name": "永昕",
 "slug": "tw-4726",
 "aliases": [
  "永昕生物醫藥股份有限公司",
  "Mycenax",
  "4726"
 ],
 "ticker": "4726",
 "industry": "生技醫療業",
 "website": "https://www.mycenax.com",
 "summary": "永昕（4726）是上櫃的生技醫療類股公司，2001 年成立，2013 年上櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "永昕生物醫藥股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "英文簡稱",
   "value": "Mycenax",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心上櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "上櫃日期",
   "value": "2013-12-25",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "成立日期",
   "value": "2001-09-28",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "董事長",
   "value": "陳佩君",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "總經理",
   "value": "陳佩君",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "實收資本額",
   "value": 2070418000,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "富鋒聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "公司網址",
   "value": "https://www.mycenax.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 116375,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔來源為二手連結，回查官方115年09月營收逐欄一致；僅修source並加註，claim/value/unit/as_of均保留。出表日1151017。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": 393.28,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔來源為二手連結，回查官方115年09月營收逐欄一致；僅修source並加註，claim/value/unit/as_of均保留。出表日1151017。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": 55.41,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔來源為二手連結，回查官方115年09月營收逐欄一致；僅修source並加註，claim/value/unit/as_of均保留。出表日1151017。"
  },
  {
   "claim": "主要產品：G公司日本上市藥品",
   "value": "日本上市藥品轉廠；已簽長期供貨合約，供應日本市場",
   "unit": "",
   "as_of": "2026-06-09",
   "source": "https://www.mycenax.com/upload/2026_06_09_1645171.pdf",
   "note": "2026-06-09法說PDF第9、13頁；公司未揭露實際商品名、學名及適應症，不予推定。"
  },
  {
   "claim": "主要產品：S公司全球上市藥品",
   "value": "2025年上市商業化量產；供應歐洲、加拿大、日本等13國市場",
   "unit": "",
   "as_of": "2026-06-09",
   "source": "https://www.mycenax.com/upload/2026_06_09_1645171.pdf",
   "note": "2026-06-09法說PDF第9、13頁；公司未揭露實際商品名、學名及適應症，不予推定。"
  },
  {
   "claim": "主要產品：日本上市D藥品（DS）",
   "value": "上市藥品轉廠案進行中；原料藥（DS）專案",
   "unit": "",
   "as_of": "2026-06-09",
   "source": "https://www.mycenax.com/upload/2026_06_09_1645171.pdf",
   "note": "2026-06-09法說PDF第9、13頁；公司未揭露實際商品名、學名及適應症，不予推定。"
  },
  {
   "claim": "主要產品：日本上市L藥品（DP）",
   "value": "上市藥品轉廠案進行中；製劑（DP）專案",
   "unit": "",
   "as_of": "2026-06-09",
   "source": "https://www.mycenax.com/upload/2026_06_09_1645171.pdf",
   "note": "2026-06-09法說PDF第9、13頁；公司未揭露實際商品名、學名及適應症，不予推定。"
  },
  {
   "claim": "主要產品：R藥品",
   "value": "晚期專案進行中；公司僅公開代稱R",
   "unit": "",
   "as_of": "2026-06-09",
   "source": "https://www.mycenax.com/upload/2026_06_09_1645171.pdf",
   "note": "2026-06-09法說PDF第9、13頁；公司未揭露實際商品名、學名及適應症，不予推定。"
  },
  {
   "claim": "主要產品：F藥品",
   "value": "晚期專案進行中；公司僅公開代稱F",
   "unit": "",
   "as_of": "2026-06-09",
   "source": "https://www.mycenax.com/upload/2026_06_09_1645171.pdf",
   "note": "2026-06-09法說PDF第9、13頁；公司未揭露實際商品名、學名及適應症，不予推定。"
  },
  {
   "claim": "催化劑：日本上市D藥品（DS）",
   "value": "上市藥品轉廠案預計商業化生產｜2027（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-06-09",
   "source": "https://www.mycenax.com/upload/2026_06_09_1645171.pdf",
   "note": "PDF第13至14頁；公司只列2027，不補造季度或日期。"
  },
  {
   "claim": "催化劑：日本上市L藥品（DP）",
   "value": "上市藥品轉廠案預計商業化生產｜2027（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-06-09",
   "source": "https://www.mycenax.com/upload/2026_06_09_1645171.pdf",
   "note": "PDF第13至14頁；公司只列2027，不補造季度或日期。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-4726.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}